Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies
News Jan 27, 2012
At the Hilton San Diego Resort in San Diego, California at 11:00am. she will present the features of developed enantiomerically pure, potent and selective LSD1 inhibitors that are >1000x stronger than parnate, highly selective over related enzymes MAO-A/B, have excellent pharmacological characteristics and are active in vivo at doses of down to 0.05mpk. Other relevant aspects as the in vitro selectivity profile of our LSD1 inhibitors as well as the in vitro and in vivo response to LSD1 inhibition using FACS, IHQ, ChIP, and genome wide expression analysis will be discussed. She will finally report on the efficacy of LSD1 in different cancer xenograft models.
The TARGET AND THERAPIES session will be chaired by Dr Andrew Pope, Group Director of the Technology & Science Platform of GlaxoSmithKline who will give an Overview of Current and Developing Approaches to The Discovery of New Chemical Matter which Modulates Epigenetic Targets. In the same session, the Directors of Biology of Epizyme and Constellation Pharmaceuticals, two other companies active in the Epigenetic field, together with researchers from the Harvard Medical School will also present other interesting aspects of the field.
Epigenetics is a hot spot field in the pharmaceutical industry. It is predicted that world revenues for epigenetic therapies and technologies will reach $2.73bn in 2015 and that the overall market will grow with a CAGR of 16% between 2010 and 2015. Therapies will remain the largest source of revenue in the epigenetics market. The deal activity on the field is intense.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.